ECSP12012033A - Triple combinación para bajar la presión intraocular - Google Patents

Triple combinación para bajar la presión intraocular

Info

Publication number
ECSP12012033A
ECSP12012033A ECSP12012033A ECSP12012033A EC SP12012033 A ECSP12012033 A EC SP12012033A EC SP12012033 A ECSP12012033 A EC SP12012033A EC SP12012033 A ECSP12012033 A EC SP12012033A
Authority
EC
Ecuador
Prior art keywords
intraocular pressure
triple combination
lower intraocular
iop
revealed
Prior art date
Application number
Other languages
English (en)
Inventor
P Pujara Chetan
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43743470&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP12012033(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of ECSP12012033A publication Critical patent/ECSP12012033A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

En el presente instrumento se revelan las composiciones para disminuir la presión intraocular (PIO) de un ojo mediante la combinación de agentes que disminuyen la presión intra-ocular (PIO) bimatoprost, brimonidina y timolol. Además se revelan los métodos para reducir la PIO en el ojo de un sujeto.
ECSP12012033 2009-12-22 2012-07-11 Triple combinación para bajar la presión intraocular ECSP12012033A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28893609P 2009-12-22 2009-12-22
US36174910P 2010-07-06 2010-07-06

Publications (1)

Publication Number Publication Date
ECSP12012033A true ECSP12012033A (es) 2012-10-30

Family

ID=43743470

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP12012033 ECSP12012033A (es) 2009-12-22 2012-07-11 Triple combinación para bajar la presión intraocular

Country Status (15)

Country Link
US (1) US20130116254A1 (es)
CN (1) CN102695498A (es)
AR (1) AR079696A1 (es)
BR (1) BR112012017319A2 (es)
CL (1) CL2012001736A1 (es)
CO (1) CO6592061A2 (es)
CR (1) CR20120360A (es)
EC (1) ECSP12012033A (es)
GT (1) GT201200213A (es)
IN (1) IN2012DN06416A (es)
MX (1) MX2012007397A (es)
NI (1) NI201200112A (es)
PE (2) PE20160904A1 (es)
TW (1) TW201143773A (es)
WO (1) WO2011087790A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050244458A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular neuropathies
WO2012016000A2 (en) 2010-07-29 2012-02-02 Allergan, Inc. Preservative free brimonidine and timolol solutions
US9248135B2 (en) 2012-04-24 2016-02-02 Allergan, Inc. Prostaglandin and vasoconstrictor pharmaceutical compositions and methods of use
CA2977825A1 (en) * 2015-03-19 2016-09-22 Allergan, Inc. Fixed dose combination of brimonidine and timolol
WO2019246130A1 (en) * 2018-06-19 2019-12-26 Cella Therapeutics, Llc Sustained-release drug delivery systems comprising an intraocular pressure lowering agent, a cnp compound, an npr-b compound, a tie-2 agonist, or neurotrophic agent for use for treating glaucoma or ocular hypertension
US12042502B2 (en) * 2022-03-21 2024-07-23 Somerset Therapeutics, Llc Enhanced penetration ophthalmic compositions of bimatoprost and timolol
JP2025118563A (ja) * 2024-01-31 2025-08-13 東亜薬品株式会社 組成物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5034413A (en) 1989-07-27 1991-07-23 Allergan, Inc. Intraocular pressure reducing 9,11-diacyl prostaglandins
US5028624A (en) 1989-07-27 1991-07-02 Allergan, Inc. Intraocular pressure reducing 9,15-diacyl prostaglandins
US4994274A (en) 1989-07-27 1991-02-19 Allergan, Inc. Intraocular pressure reducing 11,15-diacyl prostaglandins and method of using
US7030149B2 (en) * 2002-04-19 2006-04-18 Allergan, Inc. Combination of brimonidine timolol for topical ophthalmic use
US7851504B2 (en) * 2005-03-16 2010-12-14 Allergan, Inc. Enhanced bimatoprost ophthalmic solution

Also Published As

Publication number Publication date
AR079696A1 (es) 2012-02-15
PE20121468A1 (es) 2012-10-28
US20130116254A1 (en) 2013-05-09
CR20120360A (es) 2012-07-30
CL2012001736A1 (es) 2012-10-12
NI201200112A (es) 2013-04-09
MX2012007397A (es) 2012-08-15
CO6592061A2 (es) 2013-01-02
BR112012017319A2 (pt) 2016-04-19
CN102695498A (zh) 2012-09-26
PE20160904A1 (es) 2016-09-16
IN2012DN06416A (es) 2015-10-09
TW201143773A (en) 2011-12-16
GT201200213A (es) 2014-08-29
WO2011087790A1 (en) 2011-07-21

Similar Documents

Publication Publication Date Title
AR120961A2 (es) Método y composición para tratar hipertensión ocular y glaucoma
CR20120360A (es) Combinación triple disminuir la presión intraocular
MY175318A (en) Androgen composition for treating an opthalmic condition
NZ597626A (en) Bicyclic compound and use thereof for medical purposes
MX2010007295A (es) Composiciones acuosas estables de ciclosporina.
UY31785A1 (es) Sistema polimerico de lagrimas artificiales
CO6571924A2 (es) Combinaciòn, kit y mètodo para reducir la presión intraocular
MX2012012941A (es) Nuevas composiciones oftalmicas.
MX2019011925A (es) Conjugados y derivados de prostaglandina para tratar el glaucoma y la hipertension ocular.
CR20130094A (es) Agonistas de adenosina a1 para el tratamiento del glaucoma y la hipertensión ocular
EP4420726A3 (en) Fixed dose combination of bromonidine and timolol
CL2012002613A1 (es) Metodo para reducir la presion intraocular que comprende suministrar un compuesto n6- ciclopentiladenosina a la camara anterior de un ojo afectado; compuestos derivados de n6- ciclopentiladenosina; composicion farmaceutica oftalmica que los comprende; y su uso para reducir la presion intraocular.
GT200600277A (es) Derivados de prostaglandina
MX2012003693A (es) Composiciones de olopatadine y usos de las mismas.
CL2011001812A1 (es) Uso de deferiprona para prevenir yotratar un trastorno ocular relacionado con hierro seleccionado de : degeneracion macular relacionada con la edad, glaucoma, cataratas, retinopatía diabetica, degeneración hereditaria de la retina, desprendiimiento de la retina, retinopatía isquémica, entre otras.
BR112012010795A2 (pt) Formulações oftálmicas contendo gama lactams substituídas e métodos para uso das mesmas
UY33562A (es) Agonistas de receptores de bradicinina y su utilización para el tratamiento de la hipertensión ocular y el glaucoma
BRPI0512525A (pt) canabidióis anormais como agentes para diminuir a pressão intraocular e fornecer efeito neuroprotetor ao olho
AR081411A1 (es) Composiciones quirurgicas que contienen agonistas de los receptores sigma
ECSP034742A (es) Combinacion de brimonidina y timolol para uso oftalmologico topico
UA66343U (ru) Способ диагностики вторичной глаукомы на глазах с измененной роговицей
UA34515U (ru) Способ улучшения оптических свойств глаза
TN2013000081A1 (en) Adenosine a1 agonists for the treatment of glaucoma and ocular hypertension
AR081546A1 (es) Composiciones oftalmicas
TR200909581A2 (tr) Kornea dikbükekliğinin azaltılmasında kullanılan dolgu maddesi